Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03381872

Intravascular Imaging- Versus Angiography-Guided Percutaneous Coronary Intervention For Complex Coronary Artery Disease

The aim of the study is to compare clinical outcomes between intravascular imaging-guided versus angiography-guided percutaneous coronary intervention (PCI) in complex lesions.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Samsung Medical Center

Seoul, 06351, South Korea

About this study

After introduction of the 2nd generation drug-eluting stents (DES), the rates of device-related failure or target lesion failure such as restenosis and stent thrombosis has been markedly decreased, compared with the era of bare metal stents or 1st generation DES. Nevertheless, patients undergoing percutaneous coronary intervention (PCI) for complex lesions, for example, chronic total occlusion (CTO), left main disease, true bifurcation lesion, long lesion, multi-vessel PCI, multiple overlapping stents, or severely calcified lesions have significantly worse clinical outcomes than those with non-complex lesions.

During the PCI procedure, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) are useful tools for providing information on preintervention lesion characteristics, including vulnerable plaques, lesion severity, length, and morphology; on postintervention optimal stent implantation for stent expansion, extension, and apposition; and on possible complications after stent implantation. Therefore, intravascular imaging guidance may improve clinical outcomes after complex PCI. However, although previous randomized controlled trial (RCT) and registries showed significantly lower rates of major adverse clinical events following IVUS-guided PCI compared with angiography-guided PCI, the RCTs were limited with small sample size and dealt with very selected lesion subsets such as CTO or long lesion. Moreover, it is uncertain whether OCT-guided PCI improves clinical outcomes compared with angiography-guided PCI. Meanwhile, appropriate imaging modality may differ according to patient and lesion characteristics.

One of the ways to maximize the advantage of intravascular imaging is choice of intravascular imaging devices by the operator's discretion. Therefore, the current RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention) is designed to investigate whether PCI under guidance of intravascular imaging devices (IVUS or OCT) chosen by operators would improve clinical outcomes compared with angiography-guided PCI in patients with complex lesions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject age ≥19 years old
  • Coronary artery disease requiring PCI
  • Patients with complex lesion
  • True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size
  • Chronic total occlusion (≥3 months) as target lesion
  • Unprotected LM disease PCI (LM ostium, body, distal LM bifurcation including non-true bifurcation)
  • Long coronary lesions (implanted stent ≥38 mm in length)
  • Multi-vessel PCI (≥2 vessels treated at one PCI session)
  • Multiple stents needed (≥3 more stent per patient)
  • In-stent restenosis lesion as target lesion
  • Severely calcified lesion (encircling calcium in angiography)
  • Ostial coronary lesion (LAD, LCX, RCA)
  • Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

Exclusion criteria

  • Target lesions not amenable for PCI by operators' decision
  • Cardiogenic shock (Killip class IV) at presentation
  • Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, or Everolimus
  • Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
  • Pregnancy or breast feeding
  • Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Unwillingness or inability to comply with the procedures described in this protocol.

Treatment and study plan

Percutaneous coronary intervention for complex lesion

Procedure

In patients who have complex coronary lesions, PCI will performed using intravascular imaging or angiography only according to the allocated arms

  • Intravascular imaging arm
  • Angiography arm
  • Definition of Complex Lesions
  • True bifurcation lesion (Medina 1,1,1/1,0,1/0,1,1) with side branch ≥2.5mm size
  • Chronic total occlusion (≥3 months) as target lesion
  • PCI for unprotected left main (LM) disease (LM os, body, distal LM bifurcation including non-true bifurcation)
  • Implanted stent length ≥38mm
  • Multi-vessel PCI (≥2 major epicardial coronary arteries treated at one PCI session)
  • Multiple stent needed (≥3 more stent per patient)
  • In-stent restenosis lesion as target lesion
  • Severely calcified lesion (encircling calcium in angiography)
  • Ostial coronary lesion (LAD, LCX, RCA)

Drug-Eluting Stent

Device

All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.

Intravascular imaging (IVUS or OCT)

Device

IVUS Reference site: Largest lumen, Plaque burden <50% Stent sizing: By measuring vessel diameter (external elastic membrane) at proximal and distal reference sites. The averaged value of the proximal and distal reference external elastic membrane diameter will be used as stent diameter

OCT Reference site: Most normal looking segment, No Lipidic plaque Stent sizing: [1] By measuring vessel diameter at the distal reference sites (in case of ≥180° of the external elastic membrane can be identified). In this case, stent diameter will be determined using mean external elastic membrane diameter at the distal reference, rounded down to the nearest 0.25 mm.

[2] By measuring lumen diameter at the distal reference sites (in case of ≥180° of the external elastic membrane cannot be identified). In this case, stent diameter will be determined using mean lumen diameter at the distal reference, rounded up to the nearest 0.25 mm.

Drug-coated Balloon

Device

All patient will be received percutaneous coronary intervention with second generation drug-eluting stent or drug-coated balloon.

Primary outcomes

  1. Target vessel Failure

    Time frame: 1-year after last patient enrollment

    A composite of cardiac death, target vessel MI, and clinically-driven target vessel revascularization

Secondary outcomes

  1. Target vessel failure without procedure-related MI

    Time frame: 1-year after last patient enrollment

    A composite of cardiac death, spontaneous target vessel MI, and clinically-driven target vessel revascularization

  2. Cardiac death or target-vessel related MI

    Time frame: 1-year after last patient enrollment

    Cardiac death or target-vessel related MI

  3. All-cause death

    Time frame: 1-year after last patient enrollment

    any death

  4. Cardiac death

    Time frame: 1-year after last patient enrollment

    cardiac death

  5. Target vessel MI with procedure-related MI

    Time frame: 1-year after last patient enrollment

    Target vessel MI with procedure-related MI

  6. Target vessel MI without procedure-related MI

    Time frame: 1-year after last patient enrollment

    Target vessel MI without procedure-related MI

  7. Any MI with procedure-related MI

    Time frame: 1-year after last patient enrollment

    Any MI with procedure-related MI

  8. Any MI without procedure-related MI

    Time frame: 1-year after last patient enrollment

    Any MI without procedure-related MI

  9. Non-target vessel related MI

    Time frame: 1-year after last patient enrollment

    Non-target vessel related MI

  10. Target lesion revascularization

    Time frame: 1-year after last patient enrollment

    TLR

  11. Target vessel revascularization

    Time frame: 1-year after last patient enrollment

    TVR

  12. Any revascularization

    Time frame: 1-year after last patient enrollment

    clinically-driven revascularization

  13. Stent thrombosis

    Time frame: 1-year after last patient enrollment

    definite stent thrombosis

  14. Incidence of contrast-induced nephropathy

    Time frame: 48-72 hours after index procedure

    CIN was defined as an increase in serum creatinine of ≥0.5mg/dL or ≥25% from baseline within 48-72 hours after contrast agent exposure

  15. Total amount of contrast use

    Time frame: Immediate after index procedure

    Total amount of contrast use during index hospitalization

  16. Total procedure time

    Time frame: Immediate after index procedure

    Total procedure time during index hospitalization

  17. Total medical cost

    Time frame: 1-year after last patient enrollment

    Total medical cost

  18. Target vessel Failure

    Time frame: 4 years after last patient enrollment

    A composite of cardiac death, target vessel MI, and clinically-driven target vessel revascularization

  19. Target vessel failure without procedure-related MI

    Time frame: 4 years after last patient enrollment

    A composite of cardiac death, spontaneous target vessel MI, and clinically-driven target vessel revascularization

  20. All-cause death

    Time frame: 4 years after last patient enrollment

    any death

  21. Cardiac death

    Time frame: 4 years after last patient enrollment

    cardiac death

  22. Target vessel MI with procedure-related MI

    Time frame: 4 years after last patient enrollment

    Target vessel MI with procedure-related MI

  23. Target vessel MI without procedure-related MI

    Time frame: 4 years after last patient enrollment

    Target vessel MI without procedure-related MI

  24. Any MI with procedure-related MI

    Time frame: 4 years after last patient enrollment

    Any MI with procedure-related MI

  25. Any MI without procedure-related MI

    Time frame: 4 years after last patient enrollment

    Any MI without procedure-related MI

  26. Non-target vessel related MI

    Time frame: 4 years after last patient enrollment

    Non-target vessel related MI

  27. Target lesion revascularization

    Time frame: 4 years after last patient enrollment

    TLR

  28. Target vessel revascularization

    Time frame: 4 years after last patient enrollment

    TVR

  29. Any revascularization

    Time frame: 4 years after last patient enrollment

    clinically-driven revascularization

  30. Stent thrombosis

    Time frame: 4 years after last patient enrollment

    definite stent thrombosis

  31. Bleeding (BARC definition)

    Time frame: 4 years after last patient enrollment

    BARC Classification (2,3, or 5)

  32. Bleeding (TIMI definition)

    Time frame: 4 years after last patient enrollment

    TIMI Classification (Minimal, Minor, Major)

Sponsors and collaborators

Lead sponsor

Samsung Medical Center

Other

Registry information

Official study title

Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention (RENOVATE-COMPLEX-PCI)

Acronym: RENOVATE

Important dates

Study start
2018
Primary completion
2022
Study completion
2025
First posted
Dec 22, 2017
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.